CS
RLAY icon

Candriam SCA’s Relay Therapeutics RLAY Stock Holding History

Candriam SCA’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-580,136
Closed -$1.52M – 714
2025
Q1 		$1.52M Sell
580,136
-1,149,063
-66% -$4.5M 0.01% 533
2024
Q4 		$7.12M Buy
1,729,199
+636,494
+58% +$3.46M 0.04% 307
2024
Q3 		$7.74M Buy
1,092,705
+389,276
+55% +$2.91M 0.04% 300
2024
Q2 		$4.59M Buy
703,429
+195,000
+38% +$1.33M 0.03% 353
2024
Q1 		$4.22M Sell
508,429
-212,641
-29% -$2.07M 0.03% 368
2023
Q4 		$7.94M Sell
721,070
-250,000
-26% -$2.11M 0.05% 283
2023
Q3 		$8.17M Hold
971,070
– – 0.06% 253
2023
Q2 		$12.2M Sell
971,070
-267,802
-22% -$3.33M 0.09% 220
2023
Q1 		$18.8M Hold
1,238,872
– – 0.13% 173
2022
Q4 		$18.5M Buy
1,238,872
+79,451
+7% +$1.52M 0.12% 176
2022
Q3 		$25.9M Buy
1,159,421
+601,604
+108% +$13.2M 0.18% 123
2022
Q2 		$9.34M Buy
557,817
+146,401
+36% +$3.14M 0.08% 232
2022
Q1 		$12.3M Sell
411,416
-118,469
-22% -$2.87M 0.08% 225
2021
Q4 		$16.3M Sell
529,885
-33,053
-6% -$1.04M 0.1% 201
2021
Q3 		$17.7M Hold
562,938
– – 0.12% 193
2021
Q2 		$20.6M Buy
562,938
+562,927
+5,117,518% +$18.6M 0.14% 172
2021
Q1 		$0 Buy
+11
New +$477 ﹤0.01% 818

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Candriam SCA's RLAY Position: Q2 2025 in Review

Candriam SCA sold out of Relay Therapeutics (RLAY) in Q2 2025, closing a stake of 580,136 shares — an estimated $1.52M sold.

Candriam SCA first reported a position in RLAY in Q1 2021 and held it in 17 quarters. The position peaked at $25.9M in Q3 2022. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

  • Candriam SCA reported no remaining Relay Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Candriam SCA sold 580,136 Relay Therapeutics shares in Q2 2025, an estimated $1.52M.
  • Candriam SCA first reported a position in Relay Therapeutics in Q1 2021 and held it in 17 quarters.
  • Candriam SCA's Relay Therapeutics position peaked at $25.9M in Q3 2022.
  • 208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.